Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
ZLAB - Zai Lab Limited
7.02(3.80%)9:00:00 PM 1/20/2021
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; and Incyte Corporation. The company was founded in 2013 and is headquartered in Shanghai, China.
Stock Chart


  • Although price ZSCore is at a high level but it has returned from prior high level and momentum has slowed down.
  • RSI is at a high level of 88. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 4.6. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics


Stock news

    Turning Point and Zai Lab Broaden Collaboration

    Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately $336 Million in Potential Milestone Payments and RoyaltiesSAN DIEGO and SHANGHAI and SAN FRANCISCO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab...

    argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China

    * Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each year * Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China * argenx to receive $75 million in upfront Zai Lab equity and $100 million in near-term milestone and other paymentsRegulated Information/Inside InformationBREDA, the Netherlands and SHANGHAI and SAN FRANCISCO, J...

    Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference

    SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 11:40 a.m. EST. The live webcast of the presentation and breakout session will be available under “Events & Presentations” in t...

    An Intrinsic Calculation For Zai Lab Limited (NASDAQ:ZLAB) Suggests It's 31% Undervalued

    Today we will run through one way of estimating the intrinsic value of Zai Lab Limited ( NASDAQ:ZLAB ) by projecting...

    The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Allakos Inc (NASDAQ: ALLK) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * Arvinas Inc (NASDAQ: ARVN) * Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) * AtriCure Inc. (NASDAQ: ATRC) * BIO-TECHNE Corp (NASDAQ: TECH) * BridgeBio Pharma Inc (NASDAQ: BBIO) * Cellectis SA (NASDAQ: CLLS) * Crispr Therapeutics A...

    Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List

    SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has been included in the updated National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA). ZEJULA (niraparib) is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor with national Category 1 designation. It has been included in the NRDL as ...

    Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

    \- Zai Lab to lead development and commercialization of CLN-081 in Greater China\- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties \- Zai Lab to join ongoing global trial for CLN-081 SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology, a biopharmaceutical company focused on developing a diversi...

    Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

    * MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial * MARGENZA is approved, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease * Product launch in U.S. anticipa...

    Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology

    SHANGHAI and SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the appointment of Alan Sandler, M.D., to the newly created position of President, Head of Global Development, Oncology, where he will lead global oncology development and related enabling functions to support the Company’s development activities. Dr. Sandler was most recently the Senior Vice President and ...